UBS Group’s Rennova Health RNVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
– Sell
-2,218
Closed -$6K – 8434
2017
Q3
$6K Buy
2,218
+596
+37% +$2.55K ﹤0.01% 7190
2017
Q2
$9K Buy
+1,622
New +$17.2K ﹤0.01% 6880
2016
Q4
– Sell
-29
Closed -$2K – 8309
2016
Q3
$2K Buy
29
+26
+867% +$3.41K ﹤0.01% 7466
2016
Q2
$1K Hold
3
– – ﹤0.01% 7626
2016
Q1
$1K Sell
3
-2
-40% -$735 ﹤0.01% 7518
2015
Q4
$3K Buy
5
+3
+150% +$5.19K ﹤0.01% 7941
2015
Q3
$5K Buy
2
+1
+100% +$2.72K ﹤0.01% 7762
2015
Q2
$4K Hold
1
– – ﹤0.01% 8022
2015
Q1
$5K Buy
+1
New +$5.2K ﹤0.01% 8150
2014
Q4
– Sell
-1
Closed -$4K – 10649
2014
Q3
$4K Buy
+1
New +$6.8K ﹤0.01% 9700
2014
Q2
– Sell
-1
Closed -$12K – 11095
2014
Q1
$12K Buy
+1
New +$15.8K ﹤0.01% 8734
2013
Q4
– Hold
0
– – – 9926
2013
Q3
– Sell
-1
Closed -$16.9K – 9478
2013
Q2
$10K Hold
1
– – ﹤0.01% 8667

UBS Group's RNVA Position: Q4 2017 in Review

UBS Group sold out of Rennova Health (RNVA) in Q4 2017, closing a stake of 2,218 shares — an estimated $6K sold.

UBS Group first reported a position in RNVA in Q2 2013 and held it in 12 quarters. The position peaked at $12K in Q1 2014. 1 fund tracked by Wall St. Rank holds RNVA as of Q4 2017.

  • UBS Group reported no remaining Rennova Health position as of Q4 2017 after selling out during the quarter.
  • UBS Group sold 2,218 Rennova Health shares in Q4 2017, an estimated $6K.
  • UBS Group first reported a position in Rennova Health in Q2 2013 and held it in 12 quarters.
  • UBS Group's Rennova Health position peaked at $12K in Q1 2014.
  • 1 fund tracked by Wall St. Rank held Rennova Health as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.